



# Save lives, save money: SGLT2 inhibitors



The George Institute  
for Global Health

Better treatments. Better care. Healthier societies.

**1.7 million Australians have diabetes.** Around **two-thirds** of diabetes patients **also have cardiovascular disease, chronic kidney disease or both**



Related hospital admissions **cost over \$6.0 billion annually**



SGLT2 inhibitors\*, a class of diabetes medication, reduce the risk of cardiovascular and kidney disease.



Making SGLT2 inhibitors more accessible in Australia will save lives and reduce costs to society.

**\$1b government investment over 10 years** in SGLT2 inhibitor treatments would mean **fewer deaths, and more cost savings.**



**-4284** acute kidney injuries



**-8744** end stage kidney disease patients



**-4148** heart attacks



and **-7450** deaths



**+ almost \$5b** in cost savings

Every **\$1 invested** returns almost **\$5** in **benefits** to society



The George Institute encourages broad access to SGLT2 inhibitors in Australia to manage cardiovascular disease risks and slow kidney disease progression. This includes amending PBS restrictions for SGLT2 inhibitors to take into account current evidence and encouraging clinicians to prescribe these to eligible patients.

\*SGLT2 inhibitors are a class of diabetes medication designed to lower glucose in type-2 diabetes patients. Evidence shows they reduce the risk of cardiovascular and kidney disease. At the moment restrictions prevent them from being used as widely as they could be, thereby preventing optimum outcomes.